Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyuki Fujimoto

Showing results (141-150 of 183) with videos related to

Pageof 19
Sort By:
International Journal of Urology : Official Journal of the Japanese Urological Association|December 31, 2013
Oncological outcomes of renal pelvic and ureteral cancer patients registered in 2005: the first large population report from the Cancer Registration Committee of the Japanese Urological AssociationHiroyuki Fujimoto, Hiroyuki Nakanishi, Tsuneharu Miki, et al.
Japanese Journal of Clinical Oncology|August 18, 2010
Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinomaYoshihiko Tomita, Nobuo Shinohara, Takeshi Yuasa, et al.
Japanese Journal of Clinical Oncology|November 10, 2009
A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safetyHirotsugu Uemura, Nobuo Shinohara, Takeshi Yuasa, et al.
International Journal of Cancer|February 8, 2014
Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptomeEri Arai, Hiromi Sakamoto, Hitoshi Ichikawa, et al.
Japanese Journal of Clinical Oncology|January 7, 2022
Risk factors for recurrence after operation in patients with pT1a renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological AssociationNobuyuki Nakajima, Akira Miyajima, Nobuo Shinohara, et al.
Carcinogenesis|June 27, 2019
Establishment of permutation for cancer risk estimation in the urothelium based on genome-wide DNA methylation analysisKoji Tsumura, Eri Arai, Ying Tian, et al.
Cancer Medicine|March 25, 2018
Importance of the site of positive surgical margin in salvage external beam radiation therapy for biochemical recurrence of prostate cancer after radical prostatectomyTairo Kashihara, Satoshi Nakamura, Akihisa Wakita, et al.
Urologic Oncology|May 18, 2010
The incidence and management of metachronous testicular germ cell tumors in patients with extragonadal germ cell tumorsKenji Hashimoto, Hiroyuki Fujimoto, Tsutomu Kouno, et al.
International Journal of Cancer|June 11, 2015
Alterations of the spindle checkpoint pathway in clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomasEri Arai, Masahiro Gotoh, Ying Tian, et al.
Cancer Science|October 22, 2009
Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancerMakito Miyake, Kokichi Sugano, Hitomi Sugino, et al.
Pageof 19

Showing results (141-150 of 183) with videos related to

Sort By:
Pageof 19
International Journal of Urology : Official Journal of the Japanese Urological Association|December 31, 2013
Oncological outcomes of renal pelvic and ureteral cancer patients registered in 2005: the first large population report from the Cancer Registration Committee of the Japanese Urological AssociationHiroyuki Fujimoto, Hiroyuki Nakanishi, Tsuneharu Miki, et al.
Japanese Journal of Clinical Oncology|August 18, 2010
Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinomaYoshihiko Tomita, Nobuo Shinohara, Takeshi Yuasa, et al.
Japanese Journal of Clinical Oncology|November 10, 2009
A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safetyHirotsugu Uemura, Nobuo Shinohara, Takeshi Yuasa, et al.
International Journal of Cancer|February 8, 2014
Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptomeEri Arai, Hiromi Sakamoto, Hitoshi Ichikawa, et al.
Japanese Journal of Clinical Oncology|January 7, 2022
Risk factors for recurrence after operation in patients with pT1a renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological AssociationNobuyuki Nakajima, Akira Miyajima, Nobuo Shinohara, et al.
Carcinogenesis|June 27, 2019
Establishment of permutation for cancer risk estimation in the urothelium based on genome-wide DNA methylation analysisKoji Tsumura, Eri Arai, Ying Tian, et al.
Cancer Medicine|March 25, 2018
Importance of the site of positive surgical margin in salvage external beam radiation therapy for biochemical recurrence of prostate cancer after radical prostatectomyTairo Kashihara, Satoshi Nakamura, Akihisa Wakita, et al.
Urologic Oncology|May 18, 2010
The incidence and management of metachronous testicular germ cell tumors in patients with extragonadal germ cell tumorsKenji Hashimoto, Hiroyuki Fujimoto, Tsutomu Kouno, et al.
International Journal of Cancer|June 11, 2015
Alterations of the spindle checkpoint pathway in clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomasEri Arai, Masahiro Gotoh, Ying Tian, et al.
Cancer Science|October 22, 2009
Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancerMakito Miyake, Kokichi Sugano, Hitomi Sugino, et al.
Pageof 19